Cargando…
Gut mycobiome as a promising preventive and therapeutic target for metabolic disorders
Autores principales: | Dalamaga, Maria, Zheng, Liaoyuan, Liu, Junli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829758/ https://www.ncbi.nlm.nih.gov/pubmed/35169691 http://dx.doi.org/10.1016/j.metop.2022.100168 |
Ejemplares similares
-
Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies()
por: Lempesis, Ioannis G., et al.
Publicado: (2022) -
Serum bilirubin to fetuin-A ratio as a prognostic biomarker in critically ill patients with sepsis
por: Karampela, Irene, et al.
Publicado: (2021) -
DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH
por: Dalamaga, Maria, et al.
Publicado: (2021) -
Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
por: Fotis, Dimitrios, et al.
Publicado: (2022) -
Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients
por: Coene, Karlien L. M., et al.
Publicado: (2018)